Purpose: TransitQA is an innovative method for Tomotherapy transit dosimetry using the on-board detector (OBD). Our previously published model for Tomotherapy treatment plan verification (AirQA) has been enhanced to take into account patient and couch transmission. AirQA estimates the OBD signal during irradiation with nothing in the beam path from the leaf control sinogram, allowing us to check whether the planned treatment is correctly delivered by the machine. TransitQA allows us to check the treatment delivery with the patient on the couch, potentially showing the effects of changes in the patient anatomy and delivery errors. Methods: Patient and couch transmission have been added to the model using the OBD projections of pretreatment megavoltage computed tomography (MVCT). The difference in the energy spectra between the imaging and treatment beams has been corrected by an exponent from the MVCT projections consisting of the ratio of the mass attenuation coefficients. This exponent has been found to not vary significantly with the atomic number Z, allowing us to apply this procedure to heterogeneous media, such as patients. The attenuated OBD projections acquired during the treatment are compared to the model via a signed global c-index analysis. The dose criterion was 5% of the 95 th percentile of the dose distribution, and the distance to agreement (DTA) was 4 mm. Results: Our method has been applied to a heterogeneous phantom with 98.1% of the points passing the c-evaluation test, showing that the model can predict the attenuated OBD projection. The method has been applied to two representative patients throughout the whole treatment, highlighting variations in the signal transmission and c-index. Conclusion: This paper establishes the proof-of-concept of transit dosimetry for all patients treated by Tomotherapy. Moreover, this method can be used as a surrogate for in vivo dosimetry.
INTRODUCTION
The complexity of modern radiation therapy has continuously increased over the past few years. Currently, highly modulated plans lead to more conformal target coverage and steeper dose gradients close to the organs at risk. In this context, verification is a particularly crucial step in the treatment preparation procedure. However, interfraction discrepancies can occur during the treatment of the patient and result in significant differences from the initial treatment plan. These variations can be caused by changes in the patient morphology and positioning, as well as by delivery errors that can occur during a specific fraction. 1 The aim of in vivo dosimetry as performed for threedimensional conformal radiotherapy (3D-CRT) is to correlate the dose inside the patient with the dose at the patient's surface. To achieve this, small detectors (usually diodes) are placed on the patient's skin on the beam axis. In vivo dosimetry performed in this manner is usually not well adapted for intensity-modulated radiation therapy (IMRT) beams. Fluence is indeed not flat for those beams, and one point of measurement is not enough to characterize the beam. Intracavitary measurements have been conducted for volumetric modulated arc therapy (VMAT) treatments, 2 but such invasive measurements are of great discomfort to the patients and cannot be performed at every treatment location. Conversely, transit dosimetry is the process of analyzing a treatment beam after it has been attenuated (usually through the patient). 3 Thus, it can serve as a valuable tool for patient treatment delivery verification. Procedures for transit dosimetry or dose recalculation have already been published for IMRT treatments [4] [5] [6] [7] and for VMAT treatments. 8, 9 For Tomotherapy treatments, some authors recalculate the dose inside the patient using a Monte Carlo model of the machine. 1 Even though this information is very valuable, this method can be performed only if the patient is entirely in the field of view of the megavoltage computed tomography (MVCT) images.
In this study, an approach to perform transit dosimetry for Tomotherapy treatments using only the on-board detector (OBD) is developed based on our previously published model. 10 The OBD response is compared to an attenuated model calculated from the sinogram determined by the treatment planning system (TPS). This method provides an absolute reference that allows us to make a comparison with any fraction, unlike the Delivery Analysis software (Accuray Incorporated, Sunnyvale, CA, USA) recently presented, 11 where treatment sinograms are compared with only the first delivered sinogram.
First, a mathematical description of the OBD response taking into account the transmission of the patient is presented. Then, the value of the ratio of the mass attenuation coefficients needed to compute the transmission is calculated. The whole procedure is validated with a plan calculated in the Tomotherapy cheese phantom. Next, a strategy to compensate for patient position corrections due to image registration is developed and validated with the plan mentioned above. Finally, two clinical cases are shown and discussed.
MATERIALS AND METHODS

2.A. Theory
2.A.1. Model
The model presented here is an extension of our previous model (AirQA, Eq. 1), which was developed for patient-specific quality assurance (DQA). AirQA links the signal from the OBD to the leaf control sinogram (from the TPS) with nothing in the beam path. 10 This model is valid for both static jaw plans and dynamic jaw plans (TomoEDGE). • the fluence sinogramŵ is the 2D array containing the fluence-like function built from the leaf control sinogram T MLC (n,p). T MLC (n,p) (originating from the TPS) is the 2D array containing the open time of each leaf n, for each projection p,
Mðx
• j is a convolution kernel.
If an object is in the beam path (in that case, the patient and the couch), then the signal contained in the detector sinogram M att (x,p) will be essentially attenuated. It is postulated that this effect can be modeled by multiplying the right hand side of Eq. 1 by T(x,p), which are the transmission profiles for each position x and projection p. Under this hypothesis, Eq. 1 becomes T(x,p) can be calculated using the projections of the daily MVCT of the patient C(x,p) performed before the treatment. However, the beam energy spectrum used to acquire the MVCT is different from the treatment beam energy spectrum. To compensate for that, the following calculation is used, assuming that a photon beam is attenuated exponentially through matter in a first approximation.
Tðx; pÞ ¼ e 
The mass attenuation coefficients appear in the exponent only as a ratio. Analogous to M norm (x,p) (Eq. 1), we define C norm (x,p) as the content of the parentheses in Eq. 7 M norm ðx; pÞ ¼ C norm ðx; pÞ l T =q l I =q Dðx; pÞ (8) If nothing is in the beam path,
, and we return to Eq. 1. The TransitQA model can be used in two different ways. If the transmission sinogram is calculated daily from the MVCT of each day, the patient transmission will be offset. Thus, only delivery errors will be shown. Conversely, the transmission sinogram can be calculated from the MVCT of the first day of treatment only. This strategy will allow us to include the effects of changes in the patient morphology and daily positioning relative to the first fraction.
2.A.3. Displacement management
Images acquired before treatment usually lead to a shift in the patient. In this configuration, the MVCT profiles are not acquired with the patient in the same position as for treatment, and a correction of the MVCT profiles is required. Note that some radiation oncology departments may perform another MVCT after the patient position correction. In that case, the profiles of the second MVCT are already acquired with the patient in the treatment position, and no correction is needed.
If only one MVCT is performed prior to treatment, patient roll, and position corrections Dh To calculate the transmission profiles in the treatment position, these position corrections need to be taken into account. The process of taking them into account in the projections p of the MVCT is developed below.
The roll correction is quite complicated to manage in its general form. Indeed, the off-axis rotation is associated with a translation in the (x 0 ,z 0 ) plane. In the case where the planning target volume (PTV) is centered with respect to the axis of rotation, the roll correction can be simply taken into account by shifting all the angles h of the MVCT projections by the roll correction Dh. This leads to the following relation:
where should be read as assignment. The general case of roll correction is developed in appendix A1. ) and a gantry angle h, (Dx,Dz) is given by the following relationship (cf. Fig. 1 ):
where (x,y,z) is the frame of reference rotating with the gantry.
For the x component of the displacement, the projection p (x) needs to be shifted by the same amount.
For the z component of the displacement, the projection p(x) needs to be dilated (or contracted). If the projection is assumed to be at the virtual isocenter,
where SAD stands for source to axis distance. If terms in D 2 are neglected, then it does not matter in which order those transformations are applied. Starting from Eq. 12 followed by 13 gives Medical Physics, 45 (1), January 2018
2.B. Systems
Measurements were performed on a Tomotherapy HD unit (Accuray Incorporated, Sunnyvale, CA, USA). The OBD was a Hitachi (Tokyo, Japan) 3 rd generation composed of 640 ionization chambers housed in an aluminum case. The Tomotherapy quality assurance (TQA) web interface was used to retrieve the raw detector sinogram M raw (a,p) and the monitor unit signal MU1(p), as well as the raw MVCT projections C raw (a,p) and the monitor unit signal MU1 C,ref (p) (a denotes the OBD channel number). To acquire M(x,p) and C (x,p), we remove the projections corresponding to the warmup phase, as well as the signals of 64 ionization chambers that are not exploitable. Since the OBD is curved, the raw sinograms are projected on a straight line perpendicular to the beam axis and tangent to the OBD. The leaf control sinogram T MLC (n,p) can be obtained from the DICOM RT file and exported via the Tomotherapy TPS. The whole process runs on a standard PC with a homemade software programmed using the Python programming language. 12 The whole analysis process takes about 10 min.
2.C. Determination of
l T =q l I =q and dependence on the atomic number Z The ratio of the mass attenuation coefficients has been determined by explicitly applying the definitions given in the theory section of l T =q and l I =q. The spectra of the treatment and imaging beams have been found in. 13 The mass attenuation coefficients have been found on the National Institute of Standards and Technology web site. 14 
2.D. Validation of the method without displacements
The method has been applied to a plan calculated in the Tomotherapy cheese phantom with two inserts of different densities. Cortical bone and lung materials with densities of 1.821 g/cm 3 and 0.280 g/cm
3
, respectively, where chosen because of their extreme physical densities compared to water. The PTV consists of two separate cylinders that partially contain the heterogeneity inserts. An image of the dose distribution can be seen in Fig. 3 in the Section 3. The plan has been calculated for 20 Gy in 10 fractions. The field size has been set to 2.5 cm static jaws and the pitch to 0.287. Those parameters are the ones that are the most used in our department for planning. The number of iterations has been set to 100. The final modulation factor was 1.875, the gantry period was 13.5 s, and the couch speed was 5.34 9 10 À1 cm/s. The phantom has been placed on the couch according to the red lasers. A first MVCT has been performed to correct for positional errors. After the corrections are applied, a second MVCT has been performed to obtain the MVCT raw projections in the same position as the treatment. Thus, no displacement exists between the MVCT and the treatment. The acquisition has been performed in "normal" mode with a slice thickness of 2 mm. The raw detector sinograms M raw (a,p) and C raw (a,p) and monitor unit signals MU1(p) and MU1 C (p) have been extracted to calculate M norm (x,p) and C norm (x,p). The processed TPS sinogram D(x,p) has been calculated using the optimal kernel parameter value of 0.232 (obtained in our AirQA study for a 2.5 cm jaw opening). 10 Equation 8 has been evaluated using a signed projection by projection 1D global c-index distribution. The dose criterion has been set to 5% of the 95 th percentile of the distribution, and the distance to agreement (DTA) criterion has been set to 4 mm.
2.E. Validation of the displacement management
The same plan as the one described above has been used. , one with the three 1-cm displacements simultaneously, and another with the cheese phantom rotated 5°without displacements.
2.F. Application of the method to clinical cases
Two patients have been chosen to test the method presented in this paper. The first case is a postoperative head & neck patient (maxillary sinus), as it is the area of treatment that is best suited to Tomotherapy. The treatment plan consists of a simultaneous integrated boost (SIB) of 66 Gy on the R1 zone and 52.8 Gy on the maxillary sinus in 33 fractions. The patient has been simulated and treated with a 5-point mask. The second case is a prostate patient, including the prostate gland and pelvic lymph nodes. The treatment plan consists of an SIB of 56 Gy on the prostate gland and seminal vesicles and 50.4 Gy on the pelvic lymph nodes in 28 fractions.
The goal was to apply the method on every fraction of the treatment. However, only 32 of the 33 datasets were exploitable in the head & neck case, and 24 of the 28 datasets were exploitable in the prostate case.
RESULTS
3.A. Determination of
l T =q l I =q and dependence on the atomic number Z Figure 2 represents the mass attenuation coefficients as a function of energy (left log-log scale), for the different investigated materials, as well as the energy spectra for the treatment and imaging beams (right log-lin scale). This figure shows, that in the energy range defined by both spectra, the mass attenuation coefficients are very close to each other.
The ratio of these coefficients is almost constant and equal to 0.825 AE 0.001 for each tested material (cf. Table I ).
Therefore, a good estimation of the transmission profiles is also expected in a heterogeneous patient.
3.B. Validation of the method without displacements
Without displacements of the cheese phantom, the percentage of points with |c| < 1 was 98.1%. On top of Fig. 3 , the slice of MVCT at a specific position with the corresponding dose distribution is presented. The bottom part of Fig. 3 shows the corresponding projection for an angle h = 180°. The normalized detector sinogram is compared with the attenuated processed TPS sinogram via a signed global c-index distribution. The transmission profile for this particular projection is also displayed. The shape of the cheese phantom and the heterogeneities are recognizable. The agreement between the normalized detector sinogram and the attenuated TPS sinogram is good, even close to the material inserts.
3.C. Validation of the displacement management
The percentage of points passing the c-index evaluation is summarized in Table II . Except for displacements only in the head-feet direction (y 0 axis), the percentage is below 95% without the displacement corrections. In contrast, it is always above 95% when the displacement corrections are applied. The percentage of points passing the c-index evaluation for the roll correction does not return to 98% after the correction is applied. This is because it is not a case where the target is a simple on-axis volume. However, the applied corrections manage to significantly increase the percentage of points passing the c-index evaluation.
3.D. Application of the method to clinical cases
Figures 4 and 5 show detailed results of a projection of a particular fraction of the treatment of the prostate patient and of the head & neck patient, respectively. The top part shows the normalized detector sinogram back-projected onto the MVCT of that particular day. The middle part also shows the same projection of the processed TPS sinogram back-projected onto the MVCT of the first day. Finally, the bottom part shows the c-index distribution back-projected onto the MVCT of that particular day. This way of looking at results can help identify the areas that could justify differences between the normalized detector sinogram and the processed TP sinogram. On this particular projection, the agreement is worse at the soft tissue-bone interface. is quite constant throughout the treatment and never falls below 97%. Delivery errors and changes in the patient morphology and positioning, however, show a larger variation. Since the head region does not change much during the period of treatment, the larger variations may be mainly due to position difference. The bottom part of the figure shows results for the prostate patient. The rate of delivery errors is also quite constant, even though its variation is larger than that in the head & neck case. This might be explained by the fact that the prostate PTV is larger than the head & neck PTV (at least in the pelvic lymph node region), and thus, more leaves are used to deliver the dose. Delivery errors and changes in the patient morphology and positioning also show a larger variation. Additionally, the variation is larger than that of the head & neck patient, which is to be expected, as the pelvic region changes far more than the head region.
DISCUSSION
An improvement on our previously published model (AirQA) has been derived to perform transit dosimetry on Tomotherapy patients. To take into account the transmission from the patient and couch, it was postulated that the right hand-side of Eq. 1 could be multiplied by the transmission profiles. It was determined that these transmission profiles can be calculated from the patient MVCT projections. In our clinic, an MVCT is performed everyday before treatment delivery, mainly because the patient is not positioned in the exact same place (outside the bore) as where that patient is treated (inside the bore). Hence, no additional dose has to be given to the patient to calculate the transmission profiles. This method, similar to AirQA, might suffer from couch-gantry synchronicity issues. However, since the MVCT is registered with kilovoltage computed tomography (kVCT) on a daily basis, a technical problem should be visible on the image registration. Nevertheless, it is recommended to check the couch position and speed on a regular basis (e.g., using the TQA step wedge static procedure).
In the theoretical development, a correction for the energy spectrum difference has been found, depending only on the ratio of the mass attenuation coefficients. However, Table I shows that this ratio does not vary significantly with the atomic number Z (for the investigated materials). This indicates that a unique ratio can be utilized for a homogeneous water phantom and for a heterogeneous patient. This observation was expected, as the energy range of both spectra is located in the area where Compton interactions dominate (cf. Fig. 2) .
The proposed procedure has been applied to a plan calculated in the cheese phantom with two heterogeneity inserts but without any shift between the MVCT and the treatment. The good agreement between the measured attenuated signal Images acquired before treatment generally lead to a shift of the patient. Some radiation oncology departments might perform another MVCT after the patient position correction. In that case, no correction should be applied since the patient is in the same position during the second MVCT and the treatment. However, other departments, including ours, perform only one MVCT for radiation protection purposes.
For those latter cases, a mathematical development was derived in order to take this phenomenon into account. The main hypothesis was that the imaged object needs to be small in the rotating z direction to ensure that the line integral does not change much when the phantom is shifted. However, Table II shows that shifts are well managed in every direction, even for large displacements (on the order of centimeters). Table II shows a significant increase in the number of points passing the c-index test when the correction is applied, except for the shift in the y 0 direction. This is probably because the cheese phantom is very symmetric in the y 0 direction, despite the cortical bone and lung inserts. This phenomenon is likely to be observed when the spatial distribution of densities in the patient varies slowly in the considered direction.
Our method has been applied to two patients with different treated areas. The head & neck case shows a quite good stability of delivery errors, as well as reproducibility in patient morphology and positioning. The prostate case shows a larger variation in delivery errors, which may be due to the greater number of leaves involved in the treatment. It also shows a much larger variation in the patient morphology and positioning. Indeed, it is not difficult to imagine that the pelvic region is more likely to change than the head region. Moreover, the reproducibility in positioning is greater in the head & neck area with a 5-point mask.
Our study showed that OBD-based transit dosimetry is feasible for Tomotherapy treatments. The results demonstrate that the method presented in this paper is efficient. In addition to the treatment itself, the only requirement is to have an MVCT. The patient can be partially outside the field of view because MVCT profiles are acquired with an open field (no MLC). Thus, transmission profiles are always obtained with the maximum available field size in the x direction and can cover all possible treatment field patterns. This is an advantage compared to dose recalculation techniques, 1 where the whole patient (in the transverse plane) is needed for dose calculation. Moreover, our procedure is fast and does not involve a Monte Carlo model, which is not very commonly available. However, the output does not provide dose-volume histograms (DVHs) and is less directly interpretable regarding the dose to organs. For the moment, we are still gathering data to determine the criteria for a specific fraction.
The transit dosimetry procedure presented in this study allows us to check the patient geometry at every fraction. It does not disturb the patient workflow and does not require delivering an extra dose to the patient. Changes in the patient morphology could be monitored and quantified, which helped assess whether an adaptive treatment is needed. This simple procedure can be an interesting surrogate in countries where in vivo dosimetry is mandatory, such as France. 15 In the future, simulation CT could be used as a reference transmission. In this way, the patient anatomy changes between the simulations, and a particular day of treatment could be assessed.
However, some clinical experience would be necessary to fully interpret those results. One way to use this information could be to set a minimum value below which a discussion should take place between all involved professionals. An automatic decision to replan would not be advisable without investigating the reasons why the c-index passing rate has 
CONCLUSIONS
A comprehensive procedure for transit dosimetry has been developed for Tomotherapy treatments. The procedure has been performed with TomoHelical treatments but could be easily adapted for TomoDirect treatments. This procedure is easy to implement, does not require any external device (only the OBD) and does not disturb the patient workflow. It also has the advantage of being valid when the patient is partially outside the field of view of the MVCT. 
